ClinicalTrials.Veeva

Menu

Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation

G

German Heart Center Munich

Status and phase

Unknown
Phase 4

Conditions

Atrial Fibrillation

Treatments

Procedure: external electric cardioversion
Procedure: catheter ablation

Study type

Interventional

Funder types

Other

Identifiers

NCT00196209
GE IDE No. C00705

Details and patient eligibility

About

The aim of this randomized study is to evaluate the efficacy of two different approaches for conversion of persistent atrial fibrillation, the non-invasive one (external electrical cardioversion) and the invasive one (catheter ablation).

Full description

This randomized study compares two treatment strategies in patients with persistent atrial fibrillation: Cardioversion vs. catheter ablation. Cardioversion is a low risk standard treatment option for patients with persistent atrial fibrillation. However, mid- and long term efficacy (regarding the maintenance of sinus rhythm) is low. Catheter ablation is an invasive treatment which has been reported to result in up to 60-70% of patients in stable sinus rhythm. However, it is a potentially dangerous invasive procedure with potentially fatal complications.

Comparison: External cardioversion vs. catheter ablation

Enrollment

130 estimated patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >20 years and <75 years
  • documented persistent atrial fibrillation for at least 3 months (documented in at least 2 ECGs or holter-ECGs during the previous 3 months before inclusion and persistent atrial fibrillation in a 7-d-holter)
  • documented sufficient anticoagulation for at least 4 weeks before inclusion

Exclusion criteria

  • Paroxysmal atrial fibrillation
  • NYHA IV (if recompensation is not possible)
  • Contraindication for warfarin
  • Disturbance of blood coagulation
  • Myocardial infarction, PTCA/stenting, bypass-operation, stroke, intracranial bleeding less than 3 months before
  • Reversible causes of atrial fibrillation (i.e. hyperthyroidism)
  • Pregnancy
  • LA-diameter > 55mm
  • LV-function < 30% EF
  • Aortic or mitral stenosis or regurgitation III°-IV°
  • Prosthetic valves

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

130 participants in 2 patient groups

1
Experimental group
Description:
catheter ablation to treat persistent atrial fibrillation
Treatment:
Procedure: catheter ablation
2
Experimental group
Description:
cardioversion and drug prophylaxis to treat persistent atrial fibrillation
Treatment:
Procedure: external electric cardioversion

Trial contacts and locations

1

Loading...

Central trial contact

Heidi L Estner, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems